Skip to main content

Analysts Have Conflicting Sentiments on These Financial Companies: FS KKR Capital (FSK) and Moody’s (MCO)

Tipranks - Fri Feb 27, 9:09AM CST

Analysts have been eager to weigh in on the Financial sector with new ratings on FS KKR Capital (FSKResearch Report) and Moody’s (MCOResearch Report).

Claim 50% Off TipRanks Premium

FS KKR Capital (FSK)

Truist Financial analyst Arren Cyganovich maintained a Hold rating on FS KKR Capital today. The company’s shares closed last Thursday at $11.40.

According to TipRanks.com, Cyganovich is a 5-star analyst with an average return of 16.7% and a 63.3% success rate. Cyganovich covers the Financial sector, focusing on stocks such as Blackstone Secured Lending Fund, Sixth Street Specialty Lending, and First Bancorp Puerto Rico. ;'>

FS KKR Capital has an analyst consensus of Hold, with a price target consensus of $17.00, which is a 40.5% upside from current levels. In a report released today, TipRanks – PerPlexity also downgraded the stock to Hold with a $14.00 price target.

See the top stocks recommended by analysts >>

Moody’s (MCO)

Deutsche Bank analyst Faiza Alwy maintained a Buy rating on Moody’s today and set a price target of $564.00. The company’s shares closed last Thursday at $474.30.

Alwy has an average return of 0.2% when recommending Moody’s. ;'>

According to TipRanks.com, Alwy is ranked #3012 out of 12136 analysts.

Currently, the analyst consensus on Moody’s is a Strong Buy with an average price target of $555.87, a 18.8% upside from current levels. In a report issued on February 18, Goldman Sachs also maintained a Buy rating on the stock with a $531.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.